Kaleido Biosciences Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$101M
Industry:Biotech
Founded:2015
Lead Investor(s):Fidelity, Invus
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Kaleido Biosciences's estimated annual revenue is currently $16M per year.
  • Kaleido Biosciences received $101.0M in venture funding in June 2018.
  • Kaleido Biosciences's estimated revenue per employee is $164,588
  • Kaleido Biosciences's total funding is $101M.

Employee Data

  • Kaleido Biosciences has 97 Employees.
  • Kaleido Biosciences grew their employee count by -29% last year.
  • Kaleido Biosciences currently has 5 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
InCrowd
$6.3M7410%N/A
DrugPatentWatch...
$0.6M4N/AN/A
Atomwise
$11.5M6022%$57.5M
Thermo Fisher S...
$2147.5M55189N/AN/A
DrugDev
$64.9M379N/AN/A
Document Soluti...
$21.3M148N/AN/A
Schrödinger
$60.8M47011%$193M
Advera Health A...
$2.4M12N/AN/A
Naked Biome
$0.5M4N/AN/A
Bruker Corporat...
$729.4M3228N/AN/A
Chemical Comput...
$7.7M53N/AN/A
Certara
$77.2M4518%N/A
Optibrium
$4M31N/AN/A
Olympus Life Sc...
$17.2M7610%N/A
Adjility Inform...
$0.6M4N/AN/A
De Novo Softwar...
$3.6M25N/AN/A
Genedata
$41.9M320N/AN/A
Gritstone Oncol...
$0.1M1857%$216M
American Gene T...
$3.9M30N/AN/A
Eidogen-Sertant...
$0.7M7N/AN/A
Missing a competitor? Contribute!?
Submit

Kaleido is a clinical-stage healthcare company leading the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The company is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including rare genetic disorders. Kaleido's unique discovery and development model is redefining traditional R&D, enabling product candidates to advance rapidly into the clinic, dramatically reducing time and cost. Learn more at https://kaleido.com/.

keywords:N/A

97

Number of Employees

$16M

Revenue (est)

5

Current Jobs

-29%

Employee Growth %

$101M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Yanjie GuPrincipal scientist/Associate Director
Jeffrey CehelskyVice President Clinical Operations
Michael BruceSvp Project Portfolio Alliance Mgmt
Wendy ArnoldSVP, Human Resources
Kim HocknellSr. Director, External Manufacturing
Stephen SofenSVP Techical Operations
Roberto VincentClinical Project Manager
Yan ZhengSr Director, Biostatistics
Elisa AsanzaDirector, Regulatory Affairs
Steven FukudaSr. Clinical Project Manager

Kaleido Biosciences News

12-Sep-19 - Kaleido Biosciences Inc (NASDAQ:KLDO) Sees Significant Increase in Short Interest

Kaleido Biosciences Inc (NASDAQ:KLDO) was the target of a significant growth in short interest in the month of August. As of August 31st, there ...

12-Sep-19 - Kaleido BioSciences, Inc. (NasdaqGS:KLDO) and Aimia Inc. (TSX:AIM) Stock Valuation in Focus

Kaleido BioSciences, Inc. (NasdaqGS:KLDO) currently has a Value Composite score of 88. Similarly, the Value Composite Two (VC2) is ...

12-Sep-19 - Kaleido Biosciences, Inc. (KLDO) Fell By -0.1%, But Why?

After completing its last trading session, Kaleido Biosciences, Inc. (KLDO) dropped by -0.1% – here is what that looked like (as of 2019-09-13): ...

Kaleido Biosciences Funding

DateAmountRoundLead InvestorsReference
2017-09-19$UndisclosedUndisclosedFlagship PioneeringArticle
2018-06-26$101.0MCFidelityArticle

Kaleido Biosciences Executive Hires

DateNameTitleReference
2017-09-19Mike BonneyCEO/ChairmanArticle
2017-11-02John DaviesCTOArticle
2017-12-13Alison LawtonPresident & COOArticle
2018-01-04Wendy ArnoldSVP HRArticle
2018-03-27Stephen SofenVP Technical OperationsArticle
2018-04-24Joshua BrummChief Financial OfficerArticle
2018-08-22Alison LawtonCEOArticle
2018-12-04Katharine KnobilChief Medical Officer and Head of Research & DevelopmentArticle